<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00178841</url>
  </required_header>
  <id_info>
    <org_study_id>050416</org_study_id>
    <nct_id>NCT00178841</nct_id>
  </id_info>
  <brief_title>Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL</brief_title>
  <official_title>Open Label Pilot Study of Combination Therapy With Rosiglitazone and Bexarotene to Investigate a Possible Synergism in the Treatment of Cutaneous T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine if combination therapy with rosiglitazone and
      bexarotene might have a synergistic effect in the treatment of patients with CTCL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment options for CTCL include both skin-directed and systemic therapies. Topical
      treatments are effective for early-stage disease that is localized to the skin. However,
      disease involving the lymph nodes or visceral sites can be palliated but rarely cured, even
      with the most aggressive regimens of systemic chemotherapy. Unfortunately, current treatment
      options at this stage only provide a short term response. Thus, it is important that
      additional therapies are investigated to manage this malignancy.

      Bexarotene has been approved by the FDA for the treatment of Cutaneous T-Cell Lymphoma
      (CTCL).Bexarotene binds the RXR(Retinoid X Receptor)inside the cell, a receptor that forms
      heterodimers with a multitude of other nuclear receptors. One of these is the PPARγ
      (Peroxisome Proliferator Activator Receptor Gamma), a nuclear receptor that binds
      Rosiglitazone.Rosiglitazone is an FDA approved antidiabetic agent of the Thiazolidinedione
      class. Rosiglitazone increases insulin sensitivity and is useful in the treatment of type 2
      diabetes. In vitro data suggest that rosiglitazone and bexarotene may act synergistically to
      induce apoptosis in cell lines derived from patients with cutaneous T cell lymphoma (CTCL).
      This pilot study will investigate this possible synergism in a small cohort of patients with
      stable or progressive CTCL already being treated with bexarotene.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a 50% Improvement in Baseline Skin Score</measure>
    <time_frame>16 weeks</time_frame>
    <description>mSWAT scoring. Range 0 to 400. Measured every 4 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Evaluations</measure>
    <time_frame>baseline and every 4 weeks</time_frame>
    <description>FACT-G, Functional Assessment of Cancer Therapy-General (quality-of-life scale) 0= worst 108=best</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus Score</measure>
    <time_frame>16 weeks</time_frame>
    <description>10-cm visual analog scale, 10= worst, 1=best</description>
  </secondary_outcome>
  <enrollment type="Actual">4</enrollment>
  <condition>Cutaneous T-cell Lymphoma</condition>
  <condition>Mycosis Fungoides</condition>
  <condition>Sezary Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone and Bexarotene</intervention_name>
    <description>rosiglitazone added to bexarotene capsules</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with biopsy proven persistent or recurrent cutaneous cell lymphoma (CTCL)
             Stage IA-IVA

          -  Patients with a pathologic proven diagnosis of CTCL that is documented in the patient
             history.

          -  Patient has preserved organ function.

          -  Patient has an ECOG performance status between 0 - 2.

          -  Women of childbearing potential should be screened for pregnancy prior to treatment
             and utilize effective contraceptive methods (e.g. barrier) during treatment period.

          -  Patients over the age of 18 who are willing and able to provide Informed Consent

          -  The patient has been taking Targretin capsules for at least the last 4 months and the
             dose has remained relatively stable.

          -  The patient has had stable or progressive disease over the past 4 months.

          -  Patient has adequate laboratory parameters for liver and kidney function.

        Exclusion Criteria:

          -  Patients with CD30+ Anaplastic Large Cell Lymphoma

          -  Patients with pathology consistent with peripheral T-cell lymphoma.

          -  Patients with Stage IVB (visceral involvement with CTCL).

          -  Patients with history of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis
             C infection.

          -  Patients with a diagnosis of congestive heart failure.

          -  Patients exhibiting significant edema or unstable cardiovascular disease.

          -  Patients with a fasting triglyceride level greater then 500mg/dl.

          -  Patients that have started any new treatment for CTCL in the past 4 months.

          -  Pregnant women will be excluded from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Zic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-5227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/17184879</url>
    <description>Pubmed link to article</description>
  </link>
  <reference>
    <citation>Bunn PA Jr, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med. 1994 Oct 15;121(8):592-602. Review.</citation>
    <PMID>8085692</PMID>
  </reference>
  <reference>
    <citation>Koh HK, Charif M, Weinstock MA. Epidemiology and clinical manifestations of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995 Oct;9(5):943-60. Review.</citation>
    <PMID>8522490</PMID>
  </reference>
  <reference>
    <citation>Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC; Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001 May 1;19(9):2456-71.</citation>
    <PMID>11331325</PMID>
  </reference>
  <reference>
    <citation>Zhang C, Ni X, Konopleva M, Andreeff M, Duvic M. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells. J Invest Dermatol. 2004 Aug;123(2):380-7.</citation>
    <PMID>15245439</PMID>
  </reference>
  <reference>
    <citation>Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S, Cooper DA; Rosey investigators. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet. 2004 Feb 7;363(9407):429-38.</citation>
    <PMID>14962523</PMID>
  </reference>
  <reference>
    <citation>Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol. 2004 Feb 1;93(3):362-5.</citation>
    <PMID>14759393</PMID>
  </reference>
  <reference>
    <citation>Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003 Jan;26(1):172-8.</citation>
    <PMID>12502676</PMID>
  </reference>
  <reference>
    <citation>Demierre MF, Tien A, Miller D. Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma. Arch Dermatol. 2005 Mar;141(3):325-30.</citation>
    <PMID>15781673</PMID>
  </reference>
  <reference>
    <citation>Bunn PA Jr, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep. 1979 Apr;63(4):725-8.</citation>
    <PMID>445521</PMID>
  </reference>
  <reference>
    <citation>Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, Diaz-Peréz JL, Geerts ML, Goos M, Knobler R, Ralfkiaer E, Santucci M, Smith N, Wechsler J, van Vloten WA, Meijer CJ. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997 Jul 1;90(1):354-71. Review.</citation>
    <PMID>9207472</PMID>
  </reference>
  <reference>
    <citation>Shapiro PE. Advances in the histologic diagnosis of cutaneous T-cell lymphoma. Adv Dermatol. 1996;11:255-84; discussion 285. Review.</citation>
    <PMID>8718481</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>May 27, 2014</results_first_submitted>
  <results_first_submitted_qc>January 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2016</results_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>John Zic</investigator_full_name>
    <investigator_title>Associate Professor of Medicine/Dermatology</investigator_title>
  </responsible_party>
  <keyword>Cutaneous T-cell Lymphoma</keyword>
  <keyword>CTCL</keyword>
  <keyword>Mycosis Fungoides</keyword>
  <keyword>Sezary Syndrome</keyword>
  <keyword>Bexarotene</keyword>
  <keyword>Targretin</keyword>
  <keyword>Rosiglitazone</keyword>
  <keyword>Avandia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Bexarotene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rosiglitazone and Bexarotene</title>
          <description>Patients maintained their dose of bexarotene during the study and added rosiglitazone. The initial dose of rosiglitazone was 4 mg once daily. If patients showed no response after 1 month and experienced no adverse effects, the dose was increased to a maximum of 8 mg once daily. Dose reductions of rosiglitazone or bexarotene were allowed during the study, but only if necessary to control AEs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm Study</title>
          <description>All enrolled patients received rosiglitazone in addition to oral bexarotene</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="50" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a 50% Improvement in Baseline Skin Score</title>
        <description>mSWAT scoring. Range 0 to 400. Measured every 4 weeks.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone and Bexarotene</title>
            <description>All 4 enrolled patients received rosiglitazone in addition to oral bexarotene.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a 50% Improvement in Baseline Skin Score</title>
          <description>mSWAT scoring. Range 0 to 400. Measured every 4 weeks.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Evaluations</title>
        <description>FACT-G, Functional Assessment of Cancer Therapy-General (quality-of-life scale) 0= worst 108=best</description>
        <time_frame>baseline and every 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone and Bexarotene</title>
            <description>Patients maintained their dose of bexarotene during the study and added rosiglitazone. The initial dose of rosiglitazone was 4 mg once daily. If patients showed no response after 1 month and experienced no adverse effects, the dose was increased to a maximum of 8 mg once daily. Dose reductions of rosiglitazone or bexarotene were allowed during the study, but only if necessary to control AEs.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Evaluations</title>
          <description>FACT-G, Functional Assessment of Cancer Therapy-General (quality-of-life scale) 0= worst 108=best</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.25" lower_limit="0" upper_limit="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pruritus Score</title>
        <description>10-cm visual analog scale, 10= worst, 1=best</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone and Bexarotene</title>
            <description>Patients maintained their dose of bexarotene during the study and added rosiglitazone. The initial dose of rosiglitazone was 4 mg once daily. If patients showed no response after 1 month and experienced no adverse effects, the dose was increased to a maximum of 8 mg once daily. Dose reductions of rosiglitazone or bexarotene were allowed during the study, but only if necessary to control AEs.</description>
          </group>
        </group_list>
        <measure>
          <title>Pruritus Score</title>
          <description>10-cm visual analog scale, 10= worst, 1=best</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rosiglitazone and Bexarotene</title>
          <description>All enrolled patients received rosiglitazone in addition to oral bexarotene.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>N=2 grade 3 neutropenia</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridemia and hypercholesterolemia</sub_title>
                <description>Hypertriglyceridemia and hypercholesterolemia, two expected adverse events (AEs), were limited to grade 1 because of aggressive management using omega 3 fatty acids, long-acting niacin, fenofibrate, ezetimibe, and statins (N=4).</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Zic, MD</name_or_title>
      <organization>Vanderbilt University Dermatology</organization>
      <phone>615-322-6485</phone>
      <email>john.zic@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

